ME02291B - Inhibitori apoptoze i njihove upotrebe - Google Patents
Inhibitori apoptoze i njihove upotrebeInfo
- Publication number
- ME02291B ME02291B MEP-2015-184A MEP18415A ME02291B ME 02291 B ME02291 B ME 02291B ME P18415 A MEP18415 A ME P18415A ME 02291 B ME02291 B ME 02291B
- Authority
- ME
- Montenegro
- Prior art keywords
- peptide
- conjugate
- pharmaceutical composition
- peptidomimetic
- ischemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (17)
1. Peptid koji se sastoji od: - fragmenta od 16, 17, 18, 19, 20, 21, 22, 23 ili 24 uzastopna amino kisjelinska ostatka od DAXX proteina od SEQ ID BR: 1, gdje pomenuti fragment obuhvata sekvencu amino kisjeline iznetu u SEQ ID BR: 5, gdje je pomenuti peptid sposoban da inhibira ćelijski apoptozis.
2. Peptid u skladu sa zahtjevom 1, gdje je pomenuti peptid fragment DAXX proteina koji se sastoji od sekvence amino kisjeline iznete u SEQ ID BR: 5 ili u bilo kom od SEQ ID BR: 17-44.
3. Peptidomimetik peptida u skladu sa zahtjevom 1 ili zahtjevom 2.
4. Konjugat koji obuhvata peptid u skladu sa zahtjevom 1 ili zahtjevom 2 ili peptidomimetik u skladu sa zahtjevom 3 vezan za peptid koji prodire u ćeliju.
5. Konjugat u skladu sa zahtjevom 4, gde je pomenuti peptid ili pomenuti peptidomimetik vezan preko veznika za peptid koji prodire u ćeliju.
6. Konjugat u skladu sa zahtjevom 4 ili zahtjevom 5, gdje je pomenuti peptid koji prodire u ćeliju odabran od grupe koja se sastoji od Tat, RXR, Bpep i Pip2b.
7. Konjugat u skladu sa zahtjevom 6, gdje se pomenuti konjugat sastoji od sekvence amino kiseline iznete u SEQ ID BR: 58, ili SEQ IQ BR: 61.
8. Farmaceutska kompozicija koja obuhvata efektivnu količinu najmanje jednog peptida u skladu sa zahtjevom 1 ili zahtjevom 2, ili najmanje jedan peptidomimetik u skladu sa zahtjevom 3, ili najmanje jedan konjugat u skladu sa bilo kojim od zahtjeva 4-7, i najmanje jedan farmaceutski prihvatljiv nosač ili eksicipijens.
9. Farmaceutska kompozicija iz zahtjeva 8 koja dalje obuhvata najmanje jedan dodatni biološki aktivni agens.
10. Farmaceutska kompozicija u skladu sa zahtjevom 9, gdje je pomenuti najmanje jedan dodatni biološki aktivni agens odabran iz grupe koja se sastoji od ciklosporina A, BH4, i njihovih kombinacija.
11. Peptid u skladu sa zahtjevom 1 ili zahtjevom 2, ili peptidomimetik u skladu sa zahtjevom 3, ili konjugat u skladu sa bilo kojim od zahtjeva 4-7 ili farmaceutska kompozicija iz bilo kog od zahtjeva 8-10, za upotrebu u metodu tretmana humanog ili životinjskog tijela.
12. Peptid u skladu sa zahtjevom 1 ili zahtjevom 2, ili peptidomimetik u skladu sa zahtjevom 3, ili konjugat u skladu sa bilo kojim od zahtjeva 4-7 ili farmaceutska kompozicija iz bilo kog od zahtjeva 8-10, za upotrebu u metodu za inhibiranje ćelijske apoptoze u tijelu čovjeka ili životinje.
13. Peptid u skladu sa zahtjevom 1 ili zahtjevom 2, ili peptidomimetik u skladu sa zahtjevom 3, ili konjugat u skladu sa bilo kojim od zahtjeva 4-7 ili farmaceutska kompozicija iz bilo kog od zahtjeva 8-10, za upotrebu u metodu za treatman akutnog infarkta miokarda, cerebralnog infarkta, transplantacije organa, intervencija na srcu, ili akutnih poremećaja cirkulacije, u tijelu čovjeka ili životinje.
14. Peptid u skladu sa zahtjevom 1 ili zahtjevom 2, ili peptidomimetik u skladu sa zahtjevom 3, ili konjugat u skladu sa bilo kojim od zahtjeva 4-7 ili farmaceutska kompozicija iz bilo kog od zahtjeva 8-10, za upotrebu u metodu za treatman ishemije u tijelu čovjeka ili životinje.
15. Peptid, ili derivat, ili konjugat, ili farmaceutska kompozicija za upotrebu u skladu sa zahtjevom 14, gdje je ishemija srčana ishemija, bubrežna ishemija, ishemični kolitis, mezenterična ishemija, moždana ishemia, ishemia udova ili ishemija kože.
16. Peptid u skladu sa zahtjevom 1 ili zahtjevom 2, ili peptidomimetik u skladu sa zahtjevom 3, ili konjugat u skladu sa bilo kojim od zahtjeva 4-7 ili farmaceutska kompozicija iz bilo kog od zahtjeva 8-10, za upotrebu u metodu za treatman reperfuzione povrede u tijelu čovjeka ili životinje.
17. Peptid, ili derivat, ili konjugat, ili farmaceutska kompozicija za upotrebu u skladu sa bilo kojim od zahtjeva 12-16, gdje pomenuti metod takođe obuhvata korak davanja ciklosporina A i/ili BH4 pomenutom humanom ili životinjskom tijelu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2010/003158 WO2012066376A1 (en) | 2010-11-18 | 2010-11-18 | Inhibitors of apoptosis and uses thereof |
| PCT/EP2011/070404 WO2012066103A2 (en) | 2010-11-18 | 2011-11-17 | Inhibitors of apoptosis and uses thereof |
| EP11785011.5A EP2640739B1 (en) | 2010-11-18 | 2011-11-17 | Inhibitors of apoptosis and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02291B true ME02291B (me) | 2016-02-20 |
Family
ID=43880951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-184A ME02291B (me) | 2010-11-18 | 2011-11-17 | Inhibitori apoptoze i njihove upotrebe |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9814758B2 (me) |
| EP (2) | EP2982685B1 (me) |
| JP (1) | JP6204828B2 (me) |
| KR (2) | KR102017645B1 (me) |
| CN (2) | CN106188271B (me) |
| AU (1) | AU2011331103B2 (me) |
| BR (1) | BR112013012362A2 (me) |
| CA (2) | CA2816827C (me) |
| CL (1) | CL2013001411A1 (me) |
| CO (1) | CO6700879A2 (me) |
| CR (1) | CR20130190A (me) |
| CY (1) | CY1118022T1 (me) |
| DK (1) | DK2640739T3 (me) |
| EA (1) | EA027336B1 (me) |
| ES (2) | ES2653734T3 (me) |
| GE (1) | GEP201606514B (me) |
| GT (1) | GT201300117A (me) |
| HR (1) | HRP20151165T1 (me) |
| HU (1) | HUE026150T2 (me) |
| IL (2) | IL226005B (me) |
| MA (1) | MA34670B1 (me) |
| ME (1) | ME02291B (me) |
| MX (1) | MX345594B (me) |
| MY (1) | MY170604A (me) |
| NI (1) | NI201300045A (me) |
| NZ (1) | NZ610620A (me) |
| PH (1) | PH12013500843A1 (me) |
| PL (1) | PL2640739T3 (me) |
| PT (1) | PT2640739E (me) |
| RS (1) | RS54422B1 (me) |
| RU (1) | RU2582247C2 (me) |
| SG (1) | SG190681A1 (me) |
| SI (1) | SI2640739T1 (me) |
| UA (1) | UA112420C2 (me) |
| WO (2) | WO2012066376A1 (me) |
| ZA (1) | ZA201303042B (me) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
| WO2012066376A1 (en) * | 2010-11-18 | 2012-05-24 | Centre National De La Recherche Scientifique - Cnrs - | Inhibitors of apoptosis and uses thereof |
| GB201314610D0 (en) | 2013-08-15 | 2013-10-02 | Blueberry Therapeutics Ltd | Compounds and their uses |
| CN103585618B (zh) * | 2013-10-31 | 2016-04-06 | 中山大学 | 端粒结合蛋白daxx在制备肿瘤细胞调控剂中的应用 |
| WO2017023419A1 (en) | 2015-08-05 | 2017-02-09 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
| EP3375450B1 (en) * | 2015-11-13 | 2023-06-28 | Industry - University Cooperation Foundation Hanyang University | Composition for preventing or treating an ischemic cerebrovascular disease through nasal administration |
| WO2019195693A1 (en) * | 2018-04-05 | 2019-10-10 | University Of Florida Research Foundation | Polypeptide inhibitor of de novo lipogenesis in cancer cells |
| CN108753820A (zh) * | 2018-06-07 | 2018-11-06 | 嘉兴学院 | Daxx蛋白通过激活erk信号通路促进卵巢癌腹水细胞增殖和转移 |
| CN111499717B (zh) * | 2020-04-10 | 2020-11-24 | 南京市儿童医院 | 一种脑源肽及其应用 |
| WO2023015299A2 (en) * | 2021-08-06 | 2023-02-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment and prevention of misfolded proteins |
| EP4691494A1 (en) * | 2024-08-09 | 2026-02-11 | Centre National de la Recherche Scientifique | Inhibitors of endothelial apoptosis for use in the treatment of a condition due to microvascular injury |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159731A (en) * | 1997-02-12 | 2000-12-12 | Massachusetts Institute Of Technology | Daxx, a Fas-binding protein that activates JNK and apoptosis |
| AU2002306500C1 (en) * | 2001-02-16 | 2006-09-28 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
| RU2328273C2 (ru) * | 2001-12-19 | 2008-07-10 | Рисерч Дивелопмент Фаундейшн | Липосомальная доставка соединений, основанных на витамине е |
| KR100597615B1 (ko) * | 2004-05-07 | 2006-07-10 | 주식회사 동부한농 | 인간 ＮＨＥ1 이온채널 단백질 결합제로서의 인간Ｄａｘｘ 단백질 및 그의 단편 |
| WO2010006177A2 (en) * | 2008-07-10 | 2010-01-14 | Dana-Farber Cancer Institute, Inc. | Muc1, caspase-8,and ded-containing proteins |
| WO2012066376A1 (en) * | 2010-11-18 | 2012-05-24 | Centre National De La Recherche Scientifique - Cnrs - | Inhibitors of apoptosis and uses thereof |
-
2010
- 2010-11-18 WO PCT/IB2010/003158 patent/WO2012066376A1/en not_active Ceased
-
2011
- 2011-11-17 HU HUE11785011A patent/HUE026150T2/en unknown
- 2011-11-17 UA UAA201306150A patent/UA112420C2/uk unknown
- 2011-11-17 SG SG2013034939A patent/SG190681A1/en unknown
- 2011-11-17 ME MEP-2015-184A patent/ME02291B/me unknown
- 2011-11-17 PL PL11785011T patent/PL2640739T3/pl unknown
- 2011-11-17 BR BR112013012362A patent/BR112013012362A2/pt not_active Application Discontinuation
- 2011-11-17 DK DK11785011.5T patent/DK2640739T3/en active
- 2011-11-17 PH PH1/2013/500843A patent/PH12013500843A1/en unknown
- 2011-11-17 NZ NZ610620A patent/NZ610620A/en not_active IP Right Cessation
- 2011-11-17 KR KR1020187030658A patent/KR102017645B1/ko not_active Expired - Fee Related
- 2011-11-17 PT PT117850115T patent/PT2640739E/pt unknown
- 2011-11-17 AU AU2011331103A patent/AU2011331103B2/en not_active Ceased
- 2011-11-17 CN CN201610579046.2A patent/CN106188271B/zh active Active
- 2011-11-17 WO PCT/EP2011/070404 patent/WO2012066103A2/en not_active Ceased
- 2011-11-17 RS RS20150753A patent/RS54422B1/sr unknown
- 2011-11-17 KR KR1020137015652A patent/KR101913285B1/ko not_active Expired - Fee Related
- 2011-11-17 MX MX2013005587A patent/MX345594B/es active IP Right Grant
- 2011-11-17 SI SI201130663T patent/SI2640739T1/sl unknown
- 2011-11-17 US US13/885,956 patent/US9814758B2/en active Active
- 2011-11-17 EA EA201300592A patent/EA027336B1/ru not_active IP Right Cessation
- 2011-11-17 CN CN201180055357.4A patent/CN103403023B/zh active Active
- 2011-11-17 ES ES15182520.5T patent/ES2653734T3/es active Active
- 2011-11-17 EP EP15182520.5A patent/EP2982685B1/en active Active
- 2011-11-17 RU RU2013127565/10A patent/RU2582247C2/ru not_active IP Right Cessation
- 2011-11-17 CA CA2816827A patent/CA2816827C/en active Active
- 2011-11-17 HR HRP20151165TT patent/HRP20151165T1/hr unknown
- 2011-11-17 CA CA3078178A patent/CA3078178C/en active Active
- 2011-11-17 ES ES11785011.5T patent/ES2553770T3/es active Active
- 2011-11-17 EP EP11785011.5A patent/EP2640739B1/en active Active
- 2011-11-17 JP JP2013539274A patent/JP6204828B2/ja active Active
- 2011-11-17 MY MYPI2013001678A patent/MY170604A/en unknown
- 2011-11-17 GE GEAP201113091A patent/GEP201606514B/en unknown
-
2013
- 2013-04-25 ZA ZA2013/03042A patent/ZA201303042B/en unknown
- 2013-04-28 IL IL226005A patent/IL226005B/en active IP Right Grant
- 2013-05-02 CR CR20130190A patent/CR20130190A/es unknown
- 2013-05-08 GT GT201300117A patent/GT201300117A/es unknown
- 2013-05-14 NI NI201300045A patent/NI201300045A/es unknown
- 2013-05-15 MA MA35909A patent/MA34670B1/fr unknown
- 2013-05-16 CO CO13121197A patent/CO6700879A2/es unknown
- 2013-05-17 CL CL2013001411A patent/CL2013001411A1/es unknown
-
2015
- 2015-11-17 CY CY20151101030T patent/CY1118022T1/el unknown
-
2018
- 2018-01-22 IL IL257069A patent/IL257069B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02291B (me) | Inhibitori apoptoze i njihove upotrebe | |
| AU2011272137B2 (en) | Novel peptide and use thereof | |
| JP2012176978A5 (me) | ||
| JP2016516023A5 (me) | ||
| JP2005506340A5 (me) | ||
| RU2010135532A (ru) | Лечение и предупреждение болезней сердца с использованием двух или более изоформ фактора роста гепатоцидов | |
| US12304933B2 (en) | Disease treatment drug based on mesenchymal-stem-cell mobilization | |
| CN102482323B (zh) | 新型肽及其应用 | |
| CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 | |
| KR20200022435A (ko) | 펩타이드 조성물 및 관련된 방법 | |
| ES2671143T3 (es) | Uso de péptidos para estimular la cicatrización de heridas | |
| CN108530527B (zh) | 一种多肽oa-gl21及其提纯方法与应用 | |
| RU2537560C2 (ru) | Тетрапептид и средство, обладающее церебропротекторной и антиамнестической активностями (варианты) | |
| Huo et al. | Advances in clinical studies of peptide drugs in stroke disease | |
| US20210340177A1 (en) | Bioactive peptides having high binding affinity to human muscular nicotinic acetylcholine receptor | |
| CN114364691B (zh) | 作为纤维化基质积累的抑制剂的肽 | |
| KR101796678B1 (ko) | 피부 각질 줄기세포 증식 및 활성화 활성을 갖는 트리펩티드 및 이의 용도 | |
| WO2017082690A1 (ko) | 미백, 피부 탄력, 주름 개선 및 상처치유 활성을 갖는 다기능성 피부투과 펩타이드 | |
| JPWO2022101633A5 (me) | ||
| Park et al. | Transdermal delivery and biological activity of arginine oligomer conjugation of palmitoyl tripeptide-1 | |
| CN120435484A (zh) | 用于软骨再生的肽及其用途 | |
| CN120344549A (zh) | 用于软骨再生的肽及其用途 | |
| CN120380007A (zh) | 用于软骨再生的肽及其用途 | |
| Schussheim et al. | Anti-inflammatory effects of peptide fragments of H2A histone and Oryza Sativa Japonica protein | |
| Liu et al. | POS0413 IGURATIMOD AMELIORATES BLEOMYCIN-INDUCED PULMONARY FIBROSIS VIA INHIBITINGEMT PROCESS AND NLRP3 INFLAMMASOME ACTIVATION |